News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

How Can Small Investors Access Private Deals With Big Potential?

OurCrowd

By MATTHEW KALMAN OurCrowd allows investors to stake a claim in promising startups for as little as $10,000 “Stripe, a payments startup, is one of the most successful companies to emerge from Silicon Valley in a generation. Last year, it hit a valuation of $65 billion. But in the 15 years since it was founded, there has not been a way for most individuals to invest in it,” Erin Griffith reported in The New York Times in April. “It is a problem that has vexed retail investors for years, as startups like Stripe, SpaceX and OpenAI soar to enormous valuations in the private market,” Griffith says. “By the time the companies go public a decade or more after they started, their growth has often slowed and their valuations are high.” Even if you can access such deals, the minimum investment is “often very high,” James Seyffart, a research analyst at Bloomberg Intelligence, tells Griffith. One rare access point for such private deals is OurCrowd, a global investment platform that has introduced its worldwide community of over 235,000 accredited investors to opportunities in more than 460 portfolio companies, attracting over $2.3 billion in commitments to date. The minimum investment in a single startup deal through OurCrowd can be as little as $10,000. <iframe width="560" height="315" src= https://www.youtube.com/embed/MOoAs0m2JRE?si=qS2U_CDdsArdnTip title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe> The definition of “accredited investor” varies, depending on your jurisdiction. In the U.S., the SEC sets the bar at someone with an annual income of at least $200,000, or a net worth of $1 million or more. That’s because investing in startups is a high-return, high-risk business and investors must be wealthy and sophisticated enough to realize what they are getting into. Startup companies seeking private investment generally prefer to attract VCs, institutions, pension funds and high net worth individuals who can commit at least six-figure sums. This keeps the company’s cap table clean, allowing its executives to concentrate on building their business instead of fielding phone calls from dozens of retail investors. The result: thousands of would-be investors are locked out of opportunities where startups can sometimes grow by 50x or 100x. Extending Access The OurCrowd model blows open this exclusive club, extending access to these potential blockbuster deals to thousands of investors for whom a $100,000 investment in a single company is too high, but $10,000 is attractive. “OurCrowd is enabling hundreds of thousands of investors around the world to access the exciting venture capital asset class,” says Jon Medved, OurCrowd’s founder and CEO. “It turns out that if you want to make real money today, you have to invest in startup companies before they go public. In the good old days, you could have invested in something like Amazon or Microsoft, held it from an IPO and made thousands of times your money. But today that's not possible because the private companies are going public much later.” “The smart money, the smart investor, wants to find a way to get into these exciting dynamic growth stories while they're still private,” Medved says. While SpaceX did not appear on the OurCrowd platform, members have invested in Axiom Space, selected by NASA to build the successor to the International Space Station and NASA’s new generation of space suits; Stoke Space, which is developing reusable rockets for daily launch missions; ICON, which is creating 3D-printed housing for use on the Moon; and Ursa Major, America’s only independent provider of aerospace propulsion engines for the commercial space, hypersonic and defense launch markets. Likewise, OpenAI is not available via OurCrowd, but other promising AI companies have recently attracted millions of dollars of investment and, for investors wishing to further diversify, OurCrowd also offers a dedicated AI Fund. “It’s traditionally very hard for accredited investors and even family offices to invest in individual startup investment opportunities,” says Lisa Graston, OurCrowd’s associate director for Investor Relations. “You can invest via a VC fund, but then you’re relinquishing control and you’re dependent on the fund managers.” “Historically, the VC asset class has outperformed the public markets and it’s an asset class that’s really difficult to access. We are really democratizing the space,” Graston adds. To give investors added comfort, OurCrowd vets every opportunity offered on its platform and selects only a small number, invests its own money in every deal, and co-investors often include many of the world’s leading VCs and institutions. By participating through OurCrowd, smaller investors can secure access to some of the best classes of shares, anti-dilution protection and other privileges usually reserved for major shareholders. “It can be difficult to get a clear picture of the current valuation of a private company when you are investing through secondary marketplaces. When you invest with OurCrowd you are joining a funding round alongside other very experienced dealmakers, reducing the risk of investing at an outsized price compared to the current company value,” Graston says. OurCrowd is not a passive investor. It takes an active role in helping the companies added to its portfolio to succeed, often taking a seat on the board and introducing them to potential partners, customers and future investors. Recently, OurCrowd extended its offering beyond VC funds to additional private market alternatives, including venture debt, private credit and private equity funds where the entry ticket can start at half a million dollars or more. OurCrowd makes funds from top-tier managers available to investors at much lower minimums, enabling many more people to participate in these opportunities. “The innovation wave, which is changing all of our lives – whether telemedicine or e-commerce or climate change – is going to be led by entrepreneurs who are backed by smart money and smart investors,” Medved says. “OurCrowd is where those entrepreneurs meet the smart money on a global basis, where they can work together to benefit everyone.” For more information about investing in startups with OurCrowd, click HERE. Featured photo courtesy of OurCrowd. OurCrowd was started in 2013, driven by the idea that the business of building startups grows bigger and better when the global ‘crowd’ gains access to VC-level investment opportunities.Today, OurCrowd is a global venture and alternative investing platform that empowers institutions and individuals to invest and engage in emerging companies. OurCrowd vets and selects companies, invests its capital, and provides its global network with unparalleled access to co-invest and contribute connections, talent and deal flow. OurCrowd builds value for its portfolio companies throughout their lifecycles, providing mentorship, recruiting industry advisors, navigating follow-on rounds and creating growth opportunities through its network of multinational partnerships. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Lisa Graston lisa.graston@ourcrowd.com Company Website http://www.ourcrowd.com

May 03, 2024 09:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

5thScape to list its first game “MMA Cage Conquest” on Meta Store: Ultimate Virtual MMA Experience

Spark Metro PR

Mixed Martial Arts fans and enthusiasts, your virtual fighting dreams have arrived! 5th Scape delivers a transformative experience with "MMA Cage Conquest," stepping far beyond traditional fighting games into true sensory immersion. Step into the iconic MMA cage, feel the roar of the crowd and become the champion you always envisioned. The 5thScape Project is an ambitious venture that aims to create a comprehensive Virtual Reality ecosystem. In this VR ecosystem many developers, gamers and experts from various industries can collaborate. This is a VR gaming studio startup in which they focus on developing games, movies, animations etc. Apart from this, they are also planning to launch a special VR headset and a VR Chair which is an ergonomically perfect chair for long gaming sessions. Now, coming back to the game, - "MMA Cage Conquest" redefines virtual combat. Its skill-based system demands true martial arts strategy along with honed reflexes. Learn and master strikes like a real-life wrestling professional. It includes (not limited to) powerful grappling throws and the intricacies of ground control to secure your victories. Feel the impact of every blow, the thrill of a perfectly executed submission, and the tension of a match fought on the razor's edge. Training lies at the heart of "MMA Cage Conquest." This journey transcends button-mashing and enters the realm of personal development. Start as an eager underdog, mastering the fundamentals through rigorous simulations. Refine your striking, defense, and ground game, tracking your progression and building unshakeable confidence. With each session, you don't just play the game – you live the fight. MMA Cage Conquest is all set to make gaming experiences more vigorous and a powerhouse for the senses. Feel the rush in your bones as you climb the leaderboards, and establish yourself as the ultimate MMA cage conqueror. Ready to unleash your inner champion? " MMA Cage Conquest " will be available on the Meta platform. Submitted for listing on May 2, 2024, the developers await approval from Meta. Visit 5thscape.com for trailers, release updates, and the latest news on your journey to become the undisputed MMA Cage Conqueror. Contact Details 5th Scape 5thScape Team +1 302-597-6768 Team@5thscape.com Company Website https://5thscape.com

May 03, 2024 06:51 AM Eastern Daylight Time

Video Image
Article thumbnail News Release

AmeriLife Names Juan Carlos Moreno National Sales Director for ACA

AmeriLife

AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions, announced today that Juan Carlos (JC) Moreno has been hired as AmeriLife’s national sales director for Affordable Care Act (ACA) products. Reporting to AmeriLife’s Senior Vice President of Managed Care Solutions, Matthew Graham, Moreno will develop the company’s carrier partnerships around ACA and under-65 products and provide sales leadership, education, and training to its principals, marketers, and licensed health insurance agents with the goal of expanding the ACA and under-65 business across AmeriLife’s distribution groups. “I’m thrilled to welcome JC to AmeriLife and the Managed Care Solutions team,” said Graham. “JC is a proven sales leader, motivator, and trainer. His deep knowledge of ACA and under-65 products will be critical to helping us grow our footprint in this expanding market.” “As the health insurance landscape continues to evolve, ACA and under-65 products provide us with a unique opportunity to train agents to meet an entirely new generation of consumers where they are today to better serve their health care needs in their retirement years,” added Scotty Elliott, Chief Distribution Officer for AmeriLife Health. “JC’s addition is a testament to our continued focus to deliver holistic solutions to consumers, and we look forward to his contributions.” Moreno comes to AmeriLife with over 20 years of business and sales experience, most recently at Elite Health Insurance, an ACA-focused health insurer where he served as director of sales and business development. Prior to Elite, Moreno held various business consultant and sales leadership roles, including territory sales manager and general manager for insurance consumer solutions platform Assurance IQ. “I am delighted to start this journey with Amerilife and the Managed Care Solutions team,” said Moreno. “I am eager to contribute my expertise and join their efforts in navigating the ever-changing landscape of ACA and under-65 health insurance.” ### About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as an industry leader in developing, marketing and distributing life and health insurance, annuities, and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a national distribution network of over 300,000 agents and financial professionals and more than 120 marketing organizations and insurance agencies. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado media@amerilife.com Partnership Inquiries Patrick Nichols corporatedevelopment@amerilife.com Company Website https://amerilife.com/

May 02, 2024 09:00 AM Eastern Daylight Time

Article thumbnail News Release

American Heart Association Honors Centre for Neuro Skills with Group Stroke Hero Award

Centre for Neuro Skills

American Heart Association (AHA) awarded Centre for Neuro Skills, a leading brain injury and rehabilitation provider, with the Group Stroke Heroes award. The group hero award recognizes a group committed to educating, inspiring, and bringing awareness to stroke. CNS was selected among other stroke support groups, stroke teams, families, private associations, medical facilities and more. CNS’ mission is to provide quality post-acute neurorehabilitation to stroke and traumatic brain injury survivors, helping them to regain their independence. Its group of physicians, researchers, clinicians, and therapists deliver innovative therapy treatment to stroke patients to reduce disability and maximize independence. CNS regularly partners with organizations like AHA and the Brain Injury Association of America to raise funds, awareness, and education for stroke prevention and rehabilitation. In 2023, CNS raised more than $26,000 for innovative research and education to fight against heart disease and stroke through the participation of four American Heart Association Heart Walks in Dallas, Tarrant County, Kern County, and Austin. CNS President and Chief Executive Officer David Harrington chaired the Kern County Heart Walk, while Dr. Matthew Ashley, Chief Medical Officer, joined the Executive Leadership Team in Austin County. Clinicians and staff across all seven CNS locations hosted fundraisers, silent auctions, and events - all geared toward raising money for the Heart Walks. “We at Centre for Neuro Skills are all so proud and honored to be recognized with the Group Stroke Hero Award by the American Heart Association,” said David Harrington, president and chief executive officer of Centre for Neuro Skills. “I want to thank our entire CNS team for their tireless dedication to helping our stroke patients receive the best possible rehabilitation therapy.” In addition to community involvement, CNS’ experts educate the public about stroke through CNS’ media platforms, website, continuing education webinars, contributed content and media interviews. CNS regularly invites stroke survivors to share their stories through their online blog and YouTube channel, showcasing the different types of strokes, the causes of strokes, and their journeys to recovery. AHA also selected one of CNS’ patients, Craig Northcutt, who received the Stroke Survivor Hero award, recognizing an individual who has survived a stroke and used their experience to educate, inspire and bring awareness about stroke. To learn more about Centre for Neuro Skills (CNS) and its brain injury rehabilitation programming, visit www.neuroskills.com. *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. # # # Contact Details Landis Communications Inc. Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

May 01, 2024 10:10 AM Pacific Daylight Time

Image
Article thumbnail News Release

TOWER CAPITAL GROUP SPONSORS A GLOBAL INVESTMENT CONSORTIUM

TOWER CAPITAL GROUP

TOWER CAPITAL GROUP, market maker of Generational Health, defines the trillion dollar category as pivotal to evolutionary capacity, country competitiveness, and global health. In a recent publication TOWER reveals that a critical lever for Generational Health is Women’s Health. TOWER states that funding women’s health innovation is a requirement for Generational Health and has committed to support this effort at a global scale. In demonstration of this commitment, TOWER expands its relationship with the Centre for Health and Healthcare at The World Economic Forum, and is the lead champion and sponsor of a first-in-kind global women’s health investment consortium. The Consortium, ”Global Women’s Health Responsible Investment Consortium” is designed to serve the global need for innovation in women’s health. Not only to be a channel of investment, but responsible and sustainable funding for the category. The Consortium serves to: Unite Global Investors with Global Innovators for Women’s Health Outcomes Accelerate and Measure Commitments to Funding and Secure Matching Commitment to select Innovators Leverage The World Economic Forum and Global Alliance for Women’s Health Platform to Curate Investment Outcomes Amplify Tower Capital’s Collective of ~1000+ Innovators Open the Aperture of Women’s Health Through the Lens of Generational Health “There is nothing more important than actualizing innovation and scientific breakthroughs for women, to ensure Generational Health.” Sanskriti Thakur, TOWER CAPITAL GROUP Founder and Chairwoman. “In collaboration with TOWER CAPITAL, we are delighted to launch the First Global Responsible Investment Consortium for Women’s Health. Together, let’s bridge the funding gap and unlock innovation for better health outcomes for all women.“ Shyam Bishen, Head, Centre for Health & Healthcare, The World Economic Forum. About TOWER: Operating across industries, regions and partners, TOWER CAPITAL GROUP and its affiliates deploy expertise and capital to uncover economic value, investment, and innovation within Generational Health and bring it to stakeholders across the globe. Generational Health are those effects passed on genetically, epigenetically, and environmentally, shaping humanity’s evolutionary curve. It represents a multi-trillion-dollar opportunity encompassing critical areas of community, environment, and women’s health. Visit www.towercapital.org for more information on Generational Health, the company, and its mission. Investor Inquiries: Sheri Bailey sheri@towercapital.org Contact Details For Media Inquiries please contact TOWER CAPITAL GROUP contact@towercapital.org Company Website https://towercapital.org/

May 01, 2024 12:00 PM Eastern Daylight Time

Article thumbnail News Release

CEO Roby Zomer discusses Argent BioPharma's future in pharmaceuticals

Argent BioPharma Ltd

Argent BioPharma managing director and CEO Roby Zomer speaks to Proactive's Stephen Gunnion following the company's rebranding from MGC Pharmaceuticals, alongside a comprehensive restructuring. Zomer explained the shift marks a refined focus on the pharmaceutical sector, discarding previous activities not aligned with pure pharmaceutical processes. Zomer highlighted the company’s advancement in drug discovery, particularly through a multidisciplinary approach and modern technologies such as nanotechnology and mRNA modulation. These innovations are targeted at addressing unmet medical needs. The company has developed notable products including CannEpil and CimetrA. CannEpil targets refractory epilepsy and has shown efficacy in controlling seizures without reported adverse events. CimetrA, developed during the COVID-19 pandemic, is designed to alleviate COVID-19 symptoms and prevent cytokine storms, with potential applications in treating other autoimmune diseases. Both drugs are now being prescribed in key markets including the United States and Europe. Zomer expressed optimism about the future, emphasizing ongoing research and progress in obtaining regulatory approvals. The focus will remain on enhancing early patient access schemes, which are expected to significantly impact revenue. Over the next 24 months, Argent BioPharma plans to introduce more innovative treatments to the market. Contact Details Proactive UK Proactive UK +44 20 7989 0813 UKEditorial@proactiveinvestors.com

May 01, 2024 10:07 AM Eastern Daylight Time

Video
Article thumbnail News Release

Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal

Immunic Inc

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of extended data from the Phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting multiple sclerosis (RRMS) in the peer-reviewed journal, Neurology® Neuroimmunology & Neuroinflammation, an official journal of the American Academy of Neurology. Vitt noted that the EMPhASIS trial demonstrated a notable reduction in gadolinium-enhancing lesions by 78% and 74% in two high-dose groups compared with the placebo. These results also correlate with improvements in serum neurofilament light chain levels, consistent with recent interim phase 2 clinical data from the ongoing CALLIPER trial in progressive MS, indicating ongoing progress in the field. Vitt highlighted the study's contribution to understanding the neuroprotective and anti-inflammatory effects of the treatment under investigation. The drug's potential impact on the treatment landscape of MS, particularly its role in addressing disease progression independent of relapse activity, was emphasized. Immunic is also conducting the CALLIPER trial in progressive MS, with key results expected by April 2025. Additionally, the phase 3 ENSURE trials are actively enrolling, with projected readouts in 2026. Dr Vitt expressed optimism about the drug's unique profile, combining safety and effectiveness in potentially altering the management of all forms of MS. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

May 01, 2024 10:02 AM Eastern Daylight Time

Video
Article thumbnail News Release

Poolbeg Pharma and Silk Road Therapeutics announce strategic collaboration on novel orphan drug

Poolbeg Pharma PLC

Poolbeg Pharma PLC CEO Jeremy Skillington and Tim Coté CEO of Silk Road Therapeutics join Proactive's Stephen Gunnion with details of an exclusive 12-month option agreement with Silk Road Therapeutics for Poolbeg to acquire a novel topical drug aimed at treating oral ulcers in patients with Behçet's disease, a rare and debilitating condition. Skillington said the move is aligned with Poolbeg's strategic focus on rare and orphan diseases. Coté, with an extensive background in orphan drug approvals from his time at the FDA, highlighted the potential of the drug given its unique formulation and unmet need in the market. He explained the severe impact of Behçet's disease, underscoring the innovative potential of their topical treatment in improving the quality of life for those affected. Both CEO expressed optimism about their collaboration's potential to fast-track this novel treatment to market, leveraging Poolbeg’s and Silk Road's combined expertise. Furthermore, Skillington provided insights into Poolbeg’s financial health and strategic developments over the past year, mentioning a robust cash position of £12.2 million at the end of 2023. He emphasised the company's disciplined capital allocation and the expansion of its intellectual property portfolio. Looking ahead, Skillington outlined Poolbeg's focus on progressing its pipeline, particularly ongoing projects like POLB001 in the oncology sector, addressing cytokine release syndrome—a critical side effect in cancer immunotherapies. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 01, 2024 09:51 AM Eastern Daylight Time

Video
Article thumbnail News Release

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Cardio Diagnostics Holdings, Inc

By Jeremy Golden, Benzinga Artificial intelligence (AI) is on the cusp of transforming nearly every single industry. When it comes to healthcare, several trends have emerged. As doctors and scientists continue to innovate, the market for AI in healthcare is expanding. The AI healthcare market appears poised for growth, with a market size of $22 billion in 2023 – a number that’s expected to accelerate at a CAGR of 36.4% from 2024-2030. The market for AI in healthcare is expected to reach $187.95 billion by 2030, demonstrating the transformative shift it’s brought to the healthcare industry. AI-focused healthcare companies are driving this progress. Here is how three healthcare companies are harnessing AI’s capabilities, using technology to drive innovation, target treatments and increase access to healthcare. Driving Innovation The rapidly growing field of AI in healthcare is already coming to life at places like the Mayo Clinic, where several AI-powered medical and surgical improvements have validated new approaches to clinical care in cardiovascular medicine, neurology, oncology, radiology and other fields of medicine. AI is replacing repetitive, manual processes – such as patient data analysis – that slow down healthcare professionals. Moving forward, this new technology will drive innovation, executives at Moderna (NASDAQ: MRNA) said after inking a partnership with OpenAI, the company behind ChatGPT, in April. The move gave about 3,000 Moderna employees access to ChatGPT Enterprise, built on OpenAI’s most advanced language model, GPT-4, the Wall Street Journal reports. Moderna anticipates the integration of AI could lead to the introduction of 15 new products by 2029, the Cambridge, Mass., company said. Moderna CEO Stéphane Bancel envisions employees using ChatGPT at least 20 times a day to “reinvent all of Moderna's business processes,” leading to greater overall efficiency. Here’s one example. When developing medicines, researchers study the biological and genetic variations that cause diseases to develop. Utilizing AI to dissect medical data sets like lab results can help scientists fill in the missing pieces. AI can assist them in figuring out the root cause of the disease, helping get much-needed treatments to patients faster. AI can lift success rates to up to 50% while reducing a drug’s time-to-market, a recent Moderna study by Harvard University’s Digital Data Design Institute found. AI is already transforming Moderna and enhancing its value-creation process. The company’s position in AI-powered innovation is leading to more efficiency and scalability across the value chain due in large part to an AI-centric culture. As of October 2023, nearly 65% of Moderna employees were active AI users. They have used the tool in multiple specific functions, from customized support to meaningful improvements in workflow efficiency and efficacy. Moderna has plans to integrate AI into all aspects of the drug development life cycle. To that end, the company has launched the Moderna AI Academy to accelerate training on AI throughout the organization. Targeted Treatments In addition to advancing drug discovery, artificial intelligence is also helping treatments reach patients faster. The past decade has seen an explosion in the amount of health data available to doctors. Organizing and analyzing this much data in a timely manner, however, can be a complex and time-consuming task for the human mind, no matter how capable or intelligent the person. That’s where AI comes in. AI is enabling researchers to develop more targeted medicines, driving progress in the field of precision medicine. This trend was part of a presentation delivered by executives at Johnson & Johnson (NYSE: JNJ), who hosted a panel discussion about AI’s role in transforming healthcare at this year’s South by Southwest conference. They touched on many topics, from AI applications in drug discovery to its ability to assist doctors during clinical trials. When it comes to running clinical trials, one of the biggest challenges is quickly and efficiently recruiting and enrolling patients who meet the selection criteria. By applying AI technology to the early stages of a clinical trial, Johnson & Johnson researchers can use large anonymized datasets to identify and locate clinical research sites with patients who could potentially benefit from the Johnson & Johnson medicines that are being studied. From there, the clinical trial operations team can work to determine the likelihood of enrolling the newly identified sites into their trials. “Historically, many clinical trials have largely taken place at major academic medical centers, but we know that not all patients have access to these centers,” said Nicole Turner, Senior Director of Global Development, Data Science & Digital Health and R&D at Janssen Pharmaceuticals. “Our goal is to leverage the power of AI to bring trials to more patients, rather than waiting for patients to come to us.” According to The Wall Street Journal, Johnson & Johnson continues to make investments – to the tune of hundreds of millions of dollars – in AI and data science. The company has hired about 6,000 data science and digital experts and opened a new research facility near San Francisco, and company executives say AI will power the company’s drug discovery work and strengthen its pharmaceuticals business in the future. Increasing Access Across the country, there is a need for more accessible and systemic healthcare solutions. One company is responding by using AI to combat cardiovascular diseases globally while committing to health equity and access. AI algorithms can effectively handle and analyze extensive medical data, including DNA biomarkers such as epigenetic and genetic information. As such, the shift to digital health and AI-driven diagnostics could also have widespread impacts on the cardiovascular detection, care and management industry, helping increase access to healthcare in a timely manner across the board – especially helping underserved communities in the process. Cardio Diagnostics (NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and detection more precise, was formed to improve patient outcomes by developing and commercializing clinical tests that leverage AI-driven technology to combat cardiovascular disease. The company is behind PrecisionCHD TM, the first integrated genetic-epigenetic test for the detection of coronary heart disease (CHD), the most common type of heart disease and the cause of most heart attacks. With the introduction of PrecisionCHD, clinicians are armed with a powerful, scalable and non-invasive alternative that comes in the form of a blood-based test that uses AI, along with personalized genetic and epigenetic information, to sensitively detect the presence of CHD and use the information for more personalized patient management. Cardio Diagnostics has also developed Epi+Gen CHD TM, a powerful test that predicts the three-year risk for a CHD event, mainly a heart attack. Powered by AI-driven integrated genetics-epigenetics, the tool enables more effective decision-making and earlier interventions. Traditional diagnostic methods for CHD, often inaccessible due to the need for specialized infrastructure, can be invasive and sometimes require exposure to ionizing radiation. Additionally, some of the tests are not sensitive to all forms of CHD and can be very costly, resulting in millions of Americans left without adequate and potentially lifesaving cardiac care. Thanks to AI, PrecisionCHD has armed clinicians with a powerful, scalable and non-invasive alternative that comes in the form of a blood-based test. For rural communities where access to specialized medical facilities is limited, the implications of this advancement are particularly relevant. With only a simple blood draw needed to complete a test, PrecisionCHD offers patients in underserved areas access to state-of-the-art cardiac assessments. PrecisionCHD can be administered in primary care or telemedicine settings, significantly reducing the need for patients to travel to distant specialized clinics. This level of availability, marking a step forward toward mitigating healthcare disparities, would not be possible without AI. Featured photo by CDC on Unsplash. Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Gene Mannheimer - Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website https://cardiodiagnosticsinc.com/

May 01, 2024 08:30 AM Eastern Daylight Time

Image
1 ... 3536373839 ... 304